STAT3介导尼罗替尼在KIT变异黑色素瘤中的应答:法国皮肤癌网络II期多中心试验
这项II期多中心试验评估尼罗替尼治疗不可切除KIT变异黑色素瘤的疗效与机制。随访中肿瘤STAT3磷酸化及其效应分子BCL-2、MCL-1下降与临床应答显著相关。
要点
- 尼罗替尼在KIT外显子11或13突变黑色素瘤中最佳总缓解率20%,疾病控制率56%。
- 4例患者出现持久应答,其中3例持续应答分别为3.6年、2.8年和2.5年。
- 肿瘤STAT3磷酸化及其效应分子BCL-2、MCL-1下降与临床应答显著相关。
核心结论
- 尼罗替尼在部分KIT变异黑色素瘤患者中诱导持久应答,STAT3抑制与应答显著相关。
研究设计与样本
- 患者接受尼罗替尼400mg口服每日两次,主要终点为6个月时的缓解率(完全缓解或部分缓解,依据RECIST标准)。
- 治疗期间进行KIT测序、qPCR阵列和下游KIT效应分子免疫染色等药效学研究。
主要发现
- 6个月时尼罗替尼诱导4例患者肿瘤应答,最佳总缓解率20%,疾病控制率56%,仅限于外显子11或13突变患者。
- 4例患者出现持久应答,其中3例持续应答(两例IIIC期患者分别为3.6年和2.8年,一例IVM1b期患者为2.5年)。
- 随访中肿瘤STAT3磷酸化及其效应分子BCL-2、MCL-1下降与临床应答显著相关。
- 在KIT突变黑色素瘤细胞系M230中,尼罗替尼降低STAT3信号,STAT抑制剂与KIT抑制剂在减少细胞增殖方面同样有效。
临床怎么用
- 对于携带KIT外显子11或13突变的不可切除黑色素瘤患者,尼罗替尼可作为潜在治疗选择。
- 治疗期间监测STAT3磷酸化及其下游效应分子变化可能有助于预测尼罗替尼应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mutated oncogenic KIT is a therapeutic target in melanoma. We conducted a multicenter phase II trial on the KIT inhibitor nilotinib in patients with unresectable melanoma harboring KIT alteration. The primary endpoint was the response rate (complete response or partial response following Response Evaluation Criteria in Solid Tumors criteria) at 6 months. Pharmacodynamic studies using KIT sequencing, qPCR array, and immunostaining of downstream KIT effectors were performed during treatment. Twenty-five patients were included and received 400 mg oral nilotinib twice daily. At 6 months, nilotinib induced tumor response in four patients. The best overall response rate was 20% and the disease control rate was 56%, limited to patients harboring exon 11 or 13 mutations. Four patients exhibited durable response, including three persisting (3.6 and 2.8 years for two patients with stage IIIC and 2.5 years for one with IVM1b melanoma). A reduction in signal transducer and activator of transcription (STAT) 3 phosphorylation and its effectors (BCL-2, MCL-1) in tumors during follow-up was significantly associated with clinical response. In the KIT-mutated melanoma cell line M230, nilotinib reduced STAT3 signaling and STAT inhibitors were as efficient as KIT inhibitors in reducing cell proliferation. Our study evidences a significant association between STAT3 inhibition and response to nilotinib, and provides a rationale for future research assessing STAT inhibitors in KIT-mutated melanoma.
引用
- Delyon J, Chevret S, Jouary T, et al. STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network. J Invest Dermatol. 2017. PMID: 28843487. doi:10.1016/j.jid.2017.07.839
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。